Base de dados : MEDLINE
Pesquisa : D03.383.710.605.500.250 [Categoria DeCS]
Referências encontradas : 387 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 39 ir para página                         

  1 / 387 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25892082
[Au] Autor:Bijvank SW; Visser W; Duvekot JJ; Steegers EA; Edens MA; Roofthooft DW; Vulto AG; Hanff LM
[Ad] Endereço:Department of Obstetrics and Gynecology, Isala Clinics, Zwolle, The Netherlands. Electronic address: s.w.a.nijbijvank@isala.nl.
[Ti] Título:Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial.
[So] Source:Eur J Obstet Gynecol Reprod Biol;189:106-11, 2015 Jun.
[Is] ISSN:1872-7654
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Determine the definitive position of ketanserin and dihydralazine for treatment of severe hypertension in pregnancy. STUDY DESIGN: A single centre double blind randomized controlled trial was performed at the obstetrical tertiary high care unit of the University Medical Centre in Rotterdam, the Netherlands. Women with severe hypertension in pregnancy (diastolic blood pressure (DBP)≥110mmHg), and significant proteinuria (≥300mg/24h), and gestational age≤32 weeks were eligible for the study. All patients (n=30) received two infusions (double dummy technique): one contained the active ingredient (ketanserin or dihydralazine), the other was used for placebo. Nicardipine was used as rescue medication. The main outcome measures were persistent severe hypertension (DBP>100mmHg>120min) despite maximum dosage of study medication and prolongation of pregnancy. RESULTS: Dihydralazine was significantly more effective in lowering blood pressure than ketanserin. No significant difference in prolongation of pregnancy was seen between the two groups. After 30 inclusions, the study was stopped because of the high rate of persistent hypertension using ketanserin and the high rate of maternal side effects using dihydralazine and the apparent succesful use of the rescue drug nicardipine. CONCLUSIONS: Our results do not support the use of either dihydralazine or ketanserin for the treatment of severe hypertension in pregnancy. Future research is needed to compare nicardipine with other antihypertensive drugs currently in use for treatment of severe hypertension in pregnancy.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Di-Hidralazina/uso terapêutico
Hipertensão/tratamento farmacológico
Ketanserina/uso terapêutico
Pré-Eclâmpsia/fisiopatologia
Complicações Cardiovasculares na Gravidez/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Di-Hidralazina/efeitos adversos
Método Duplo-Cego
Feminino
Idade Gestacional
Hospitais Universitários
Seres Humanos
Hipertensão/complicações
Ketanserina/efeitos adversos
Países Baixos
Nicardipino/uso terapêutico
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antihypertensive Agents); 97F9DE4CT4 (Ketanserin); CZ5312222S (Nicardipine); PCU411F5L6 (Dihydralazine)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:150505
[Lr] Data última revisão:
150505
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150421
[St] Status:MEDLINE


  2 / 387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25219539
[Au] Autor:Niehoff MO; Niggemann B; Sternberg J; Jenkins A; Holbrook M
[Ad] Endereço:Covance Laboratories GmbH, Kesselfeld 29, 48163 Muenster, Germany. Electronic address: marc.niehoff@covance.com.
[Ti] Título:Measurement of hyper- and hypotension during repeated dose toxicity studies in either freely moving or physically restrained cynomolgus monkeys.
[So] Source:J Pharmacol Toxicol Methods;70(3):268-75, 2014 Nov-Dec.
[Is] ISSN:1873-488X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The measurement of cardiovascular endpoints in standard toxicology studies remains a challenge as the routinely used non-invasive methods require physical restraint, causing an increase of sympathetic neural activity, leading to excitement and potentially hypertension in the experimental animals. In this study, a miniature telemetry blood pressure transmitter was used to evaluate if the acute hyper- and hypotension could be detected in free moving cynomolgus monkeys as well as physically restrained animals using positive control drugs. Furthermore, as a comparator, routine high definition oscillometry (HDO) was performed in restrained animals. METHODS: Hemodynamic parameters were monitored continuously from conscious, freely moving animals following oral administration of vehicle (water) or 1 and 10mg/kg of etilefrine, and 1 and 4mg/kg of dihydralazine as positive control articles. A second dose session was performed to confirm the reproducibility of results and a third dose session combined with physical restraint procedures for blood collection and HDO measurements. RESULTS: There was a dose-dependent, statistically significant increase in the systolic blood pressure following oral doses of etilefrine at all 3 dose sessions. This effect was less apparent during session 3, probably due to the physical restraint applied for the blood sampling and HDO measurement. No differences in the blood pressure were measured using HDO. On all three dose sessions following oral doses of dihydralazine the expected statistically significant decrease in the diastolic pressure could be clearly measured even when the telemetric data recordings were combined with physical restraint. DISCUSSION: Due to the advantages of the minimally invasive telemetry technique compared to HDO and the possibility of prolonged measurement periods, it is an invaluable tool for blood pressure measurement in freely moving animals in toxicology studies.
[Mh] Termos MeSH primário: Monitorização Ambulatorial da Pressão Arterial/veterinária
Pressão Sanguínea/efeitos dos fármacos
Di-Hidralazina/toxicidade
Etilefrina/toxicidade
Macaca fascicularis/fisiologia
Restrição Física/veterinária
[Mh] Termos MeSH secundário: Administração Oral
Animais
Monitores de Pressão Arterial/veterinária
Di-Hidralazina/administração & dosagem
Relação Dose-Resposta a Droga
Etilefrina/administração & dosagem
Modelos Animais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
PCU411F5L6 (Dihydralazine); ZB6F8MY53V (Etilefrine)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:141209
[Lr] Data última revisão:
141209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140916
[St] Status:MEDLINE


  3 / 387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24687999
[Au] Autor:Chen J; Zhao X; Wang H; Chen Y; Wang W; Zhou W; Wang X; Tang J; Zhao Y; Lu X; Chen S; Wang L; Shen C; Yang S
[Ad] Endereço:Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Province Institute of Geriatrics, Nanjing, China;
[Ti] Título:Common variants in TGFBR2 and miR-518 genes are associated with hypertension in the Chinese population.
[So] Source:Am J Hypertens;27(10):1268-76, 2014 Oct.
[Is] ISSN:1941-7225
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: An animal study reported that TGF-ß1 maturation was linked to the homeostasis of blood pressure and elastogenesis of essential hypertension (EH). Recent advances require further research of TGF-ß1 receptor in EH. METHODS: A case-control study comprised of 2,012 adult hypertension case patients and 2,210 adult control subjects was conducted, and the association with blood pressure was further tested in children. Logistic regression and calculated genetic risk score were used to evaluate the effects of one single nucleotide polymorphism (SNP) and multiple SNPs on EH, respectively. RESULTS: The genetic risk score of 10 SNPs showed a significant association with hypertension; the odds ratio of the upper quartile vs. the lower quartile was 1.282 (P = 4.67 × 10(-3)). rs7256241 in miR-518 was significantly associated with diastolic blood pressure (DBP) change in control subjects (P = 0.002), and this association was also observed in children (P = 0.04). The systolic blood pressure (SBP) and DBP of female patients taking reserpine were higher with the C and G alleles of rs3773661 (P = 0.004) and rs7256241 (P = 0.002), respectively. In patients taking Zhen Ju Jiang Ya tablets, SBP and DBP decreased linearly with rs749794 (P = 0.004 and P = 0.048, respectively). SBP decreased linearly with rs1155705 (P = 0.007) and rs11709624 (P = 0.04), but increased with rs1036096 (P = 0.03) in male patients. In male patients taking Jiang Ya tablets, SBP increased linearly with rs11709624 (P = 0.007), DBP increased linearly with rs1155705 (P = 0.03) whereas decreased with rs7256241 (P = 0.04). CONCLUSIONS: Our results suggest that TGFBR2 and miR-518 harbor variants that increase the risk of EH and affect blood pressure homeostasis as well as efficacy of antihypertensive agents.
[Mh] Termos MeSH primário: Grupo com Ancestrais do Continente Asiático/genética
Medicamentos de Ervas Chinesas/uso terapêutico
Hipertensão/genética
MicroRNAs/genética
Proteínas Serina-Treonina Quinases/genética
Receptores de Fatores de Crescimento Transformadores beta/genética
[Mh] Termos MeSH secundário: Idoso
Anti-Hipertensivos/uso terapêutico
Estudos de Casos e Controles
Criança
Chrysanthemum
Clonidina/uso terapêutico
Di-Hidralazina/uso terapêutico
Combinação de Medicamentos
Feminino
Predisposição Genética para Doença
Seres Humanos
Hidroclorotiazida/uso terapêutico
Hipertensão/tratamento farmacológico
Masculino
Meia-Idade
Polimorfismo de Nucleotídeo Único
Prometazina/uso terapêutico
Reserpina/uso terapêutico
Rutina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Drug Combinations); 0 (Drugs, Chinese Herbal); 0 (MIRN518 microRNA, human); 0 (MicroRNAs); 0 (Receptors, Transforming Growth Factor beta); 0J48LPH2TH (Hydrochlorothiazide); 5G06TVY3R7 (Rutin); 8B1QWR724A (Reserpine); EC 2.7.11.1 (Protein-Serine-Threonine Kinases); EC 2.7.11.30 (transforming growth factor-beta type II receptor); FF28EJQ494 (Promethazine); MN3L5RMN02 (Clonidine); PCU411F5L6 (Dihydralazine)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140402
[St] Status:MEDLINE
[do] DOI:10.1093/ajh/hpu047


  4 / 387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22352680
[Au] Autor:Schwarte LA; Schwartges I; Scheeren TW; Schober P; Picker O
[Ad] Endereço:Department of Anaesthesiology, VU University Medical Center, Amsterdam, The Netherlands.
[Ti] Título:The differential effects of recombinant brain natriuretic peptide, nitroglycerine and dihydralazine on systemic oxygen delivery and gastric mucosal microvascular oxygenation in dogs.
[So] Source:Anaesthesia;67(5):501-7, 2012 May.
[Is] ISSN:1365-2044
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Brain natriuretic peptide has vasodilatory properties and may thus increase splanchnic perfusion and oxygenation. We compared the effects of recombinant brain natriuretic peptide on gastric mucosal microvascular haemoglobin oxygenation (reflectance spectrophotometry) and systemic variables with those of equi-hypotensive doses of two other vasodilators (nitroglycerine and dihydralazine). Chronically instrumented, healthy dogs were randomly allocated to receive on different days, one of the three drugs (nitroglycerine and dihydralazine doses titrated to reduce mean arterial pressure by ∼20%). Brain natriuretic peptide significantly increased gastric mucosal microvascular haemoglobin oxygenation selectively, i.e. without concomitant haemodynamic effects. In contrast, the other vasodilators either did not increase gastric mucosal microvascular haemoglobin oxygenation at all (nitroglycerine), or did so only with marked increases in other systemic haemodynamic variables (dihydralazine). Our data suggest a potential role of recombinant brain natriuretic peptide selectively for increasing microvascular mucosal oxygenation. Studies are required to extend these findings to the clinical setting.
[Mh] Termos MeSH primário: Di-Hidralazina/farmacologia
Mucosa Gástrica/efeitos dos fármacos
Mucosa Gástrica/metabolismo
Peptídeo Natriurético Encefálico/metabolismo
Peptídeo Natriurético Encefálico/farmacologia
Nitroglicerina/farmacologia
Consumo de Oxigênio/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Anti-Hipertensivos/farmacologia
Cães
Feminino
Mucosa Gástrica/irrigação sanguínea
Microcirculação/efeitos dos fármacos
Natriuréticos/farmacologia
Distribuição Aleatória
Vasodilatadores/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Natriuretic Agents); 0 (Vasodilator Agents); 114471-18-0 (Natriuretic Peptide, Brain); G59M7S0WS3 (Nitroglycerin); PCU411F5L6 (Dihydralazine)
[Em] Mês de entrada:1206
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:120223
[St] Status:MEDLINE
[do] DOI:10.1111/j.1365-2044.2011.07047.x


  5 / 387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21671689
[Au] Autor:Wu Y; Hu Y; Tang X; He L; Ren T; Tao Q; Qin X; Sun N; Wang H; Cao W; Wu T; Zhan S; Wang J; Chen W; Li L
[Ad] Endereço:Department of Epidemiology and Biostatistics, Peking University Health Science Center, Beijing, China.
[Ti] Título:Long-term efficacy and tolerability of a fixed-dose combination of antihypertensive agents: an open-label surveillance study in China.
[So] Source:Clin Drug Investig;31(11):769-77, 2011 Nov 01.
[Is] ISSN:1179-1918
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A fixed-dose combination (FDC) of four compounds, hydrochlorothiazide 12.5 mg, triamterene 12.5 mg, dihydralazine 12.5 mg and reserpine 0.1 mg (HTDR), is widely used as an antihypertensive treatment in China. Although HTDR has been used in China for more than 30 years, there have been few comprehensive evaluations of this treatment. OBJECTIVE: The aim of this study was to investigate the long-term efficacy and tolerability of HTDR in Chinese patients with essential hypertension. METHODS: This was a 36-month, community-based, open-label surveillance study, conducted in the Huangpu District (Shanghai, China). The study was based in local primary healthcare settings. Subjects were recruited if they had essential hypertension, were aged ≥35 years at the time of enrolment, were expected to remain in the area for 3 years, and were able to provide informed consent. Patients who had secondary hypertension, myocardial infarction or stroke within 6 months of screening, impaired renal or hepatic function, history of cardiomyopathy or chronic heart failure, or were pregnant or lactating were excluded. HTDR was administered as one or two tablets per day in the morning. If necessary, additional hydrochlorothiazide was added. Blood pressure (BP) was measured at baseline and throughout the 36-month surveillance period every 3 months. Biochemical indicators (e.g. fasting blood glucose, plasma lipid parameters, plasma sodium and potassium, plasma uric acid and serum creatinine) were also measured, and adverse events were noted. BP reductions and the rate at which patients achieved BP targets (systolic BP [SBP] <140 mmHg and diastolic BP [DBP] <90 mmHg) throughout the period were determined. Subgroup analyses by sex and age were also conducted. RESULTS: A total of 1529 patients (550 male, 979 female; mean age 65.7 years) entered the study. After the 36-month treatment period, 93.1% of patients had achieved the SBP target, 97.9% had achieved the DBP target, and 92.1% had achieved both. The mean decreases in SBP and DBP were 15.3 mmHg and 9.9 mmHg, respectively. Overall, 127 adverse events in 119 patients (7.8%) occurred during the follow-up period, most of which were mild to moderate. Plasma lipid profiles were improved after 24 months of treatment. In addition, a significant increase in plasma potassium and a significant reduction in plasma uric acid were seen. CONCLUSION: HTDR was found to have good long-term efficacy and tolerability in Chinese patients with essential hypertension.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Di-Hidralazina/uso terapêutico
Hidroclorotiazida/uso terapêutico
Hipertensão/tratamento farmacológico
Reserpina/uso terapêutico
Triantereno/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Anti-Hipertensivos/administração & dosagem
Anti-Hipertensivos/efeitos adversos
Pressão Sanguínea/efeitos dos fármacos
Determinação da Pressão Arterial
China
Di-Hidralazina/administração & dosagem
Di-Hidralazina/efeitos adversos
Quimioterapia Combinada
Feminino
Seguimentos
Seres Humanos
Hidroclorotiazida/administração & dosagem
Hidroclorotiazida/efeitos adversos
Masculino
Meia-Idade
Pacientes Ambulatoriais
Vigilância de Produtos Comercializados
Reserpina/administração & dosagem
Reserpina/efeitos adversos
Fatores de Tempo
Triantereno/administração & dosagem
Triantereno/efeitos adversos
Universidades
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0J48LPH2TH (Hydrochlorothiazide); 8B1QWR724A (Reserpine); PCU411F5L6 (Dihydralazine); WS821Z52LQ (Triamterene)
[Em] Mês de entrada:1206
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110616
[St] Status:MEDLINE
[do] DOI:10.2165/11587390-000000000-00000


  6 / 387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19910243
[Au] Autor:Yang C; Zhang Z; Wang J
[Ad] Endereço:College of Chemistry and Materials Science, Shaanxi Normal University, Xi'an, China.
[Ti] Título:Flow-injection chemiluminescence determination of dihydralazine sulfate in serum using luminol and diperiodatocuprate (III) system.
[So] Source:Spectrochim Acta A Mol Biomol Spectrosc;75(1):77-82, 2010 Jan.
[Is] ISSN:1873-3557
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A novel flow-injection chemiluminescence (CL) method for the determination of dihydralazine sulfate (DHZS) is described. The method is based on the reaction of luminol and diperiodatocuprate (K(2)[Cu(H(2)IO(6))(OH)(2)], DPC) in alkaline medium to emit CL, which is greatly enhanced by DHZS. The possible CL mechanism was first proposed based on the kinetic characteristic, CL spectrum and UV spectra. The optimum condition for the CL reaction was in detail studied using flow-injection system. The experiments indicated that under optimum condition, the CL intensity was linearly related to the concentration of DHZS in the range of 7.0x10(-9) to 8.6x10(-7) g mL(-1) with a detection limit (3sigma) of 2.1x10(-9) g mL(-1). The proposed method had good reproducibility with the relative standard deviation 3.1% (n=7) for 5.2x10(-8) g mL(-1) of DHZS. This method has the advantages of simple operation, fast response and high sensitivity. The special advantage of the system is that very low concentration of luminol can react with DPC catalyzed by DHZS to get excellent experiment results. And CL cannot be observed nearly when luminol with same concentration reacts with other oxidants, so luminol-DPC system has higher selectivity than other luminol CL systems. The method has been successfully applied to determine DHZS in serum.
[Mh] Termos MeSH primário: Anti-Hipertensivos/sangue
Cobre/química
Di-Hidralazina/sangue
Medições Luminescentes/métodos
Luminol/química
Ácido Periódico/química
[Mh] Termos MeSH secundário: Anti-Hipertensivos/química
Di-Hidralazina/química
Seres Humanos
Luminescência
Medições Luminescentes/instrumentação
Estrutura Molecular
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 10450-60-9 (Periodic Acid); 5EXP385Q4F (Luminol); 789U1901C5 (Copper); PCU411F5L6 (Dihydralazine)
[Em] Mês de entrada:1004
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:091114
[St] Status:MEDLINE
[do] DOI:10.1016/j.saa.2009.09.044


  7 / 387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18728933
[Au] Autor:Vase H; Lauridsen TG; Bech JN; Pedersen EB
[Ad] Endereço:Department of Medical Research, Holstebro Hospital and Aarhus University, Denmark. hevas@ringamt.dk
[Ti] Título:Effects of dihydralazine on renal water and aquaporin-2 excretion in humans.
[So] Source:Scand J Clin Lab Invest;69(1):45-51, 2009.
[Is] ISSN:1502-7686
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Dihydralazine is a vasodilator that lowers blood pressure, but often also leads to significant water and sodium retention. To characterize the effect of dihydralazine on renal sodium and water handling, we tested the hypothesis that dihydralazine causes water retention parallel with an increase in urinary excretion of aquaporin-2 (u-AQP2) in healthy humans. MATERIAL AND METHODS: The effect of intravenous infusion of dihydralazine in three doses (3.125 mg, 6.250 mg and 9.375 mg) on urinary AQP2, water and sodium excretion, heart rate (HR), blood pressure (BP) and vasoactive hormones was measured in a randomized, placebo-controlled, double-blind, crossover study in 17 healthy subjects. Glomerular filtration rate (GFR) and renal tubular function were determined with the continuous infusion clearance technique and vasoactive hormones with radioimmunoassays. RESULTS: Dihydralazine compared to placebo had no impact of u-AQP2 (effect of dihydralazine versus placebo +/-SE) (-0.074+/-0.048 ng/min versus -0.015+/-0.034 ng/min; p = 0.42), despite significant reductions in urine output and free water clearance after 9.375 mg of dihydralazine. Dihydralazine significantly lowered BP and increased HR, plasma levels of angiotensin II and (except after 3.125 mg) atrial natriuretic peptide, while plasma levels of vasopressin, GFR and fractional excretions of sodium and lithium were not significantly changed. CONCLUSIONS: These findings suggest that dihydralazine increases water re-absorption in the distal tubules, independently of vasopressin and of sodium re-absorption. Furthermore, our study does not support an effect of the sympathetic nervous system, the renin-angiotensin system and the natriuretic peptide system on u-AQP2 regulation.
[Mh] Termos MeSH primário: Aquaporina 2/secreção
Di-Hidralazina/farmacologia
Rim/fisiologia
Rim/secreção
Água/fisiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Anti-Hipertensivos/administração & dosagem
Anti-Hipertensivos/farmacologia
Demografia
Di-Hidralazina/administração & dosagem
Taxa de Filtração Glomerular
Saúde
Hemodinâmica/efeitos dos fármacos
Hormônios/sangue
Seres Humanos
Infusões Intravenosas
Rim/efeitos dos fármacos
Masculino
Meia-Idade
Sódio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Aquaporin 2); 0 (Hormones); 059QF0KO0R (Water); 9NEZ333N27 (Sodium); PCU411F5L6 (Dihydralazine)
[Em] Mês de entrada:0903
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080830
[St] Status:MEDLINE
[do] DOI:10.1080/00365510802295706


  8 / 387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18482603
[Au] Autor:Yang XF
[Ad] Endereço:Key Laboratory of Synthetic and Natural Functional Molecule Chemistry of Ministry of Education, Institute of Analytical Science, Department of Chemistry, Northwest University, Taibai Road #229, Xi'an 710069, China. xfyang@mail.china.com
[Ti] Título:Chemiluminescence investigation of carbon dioxide-enhanced oxidation of dihydralazine sulfate by peroxynitrite and its application to pharmaceutical analysis.
[So] Source:Anal Chim Acta;616(2):190-5, 2008 Jun 02.
[Is] ISSN:1873-4324
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A weak chemiluminescence (CL) emission was observed upon mixing peroxynitrite (ONOO(-)) with dihydralazine sulfate (DHZS). Further experiments showed that carbonate media could enhance the CL emission significantly. Based on these observations, a novel flow injection CL method for the determination of DHZS is developed. The CL signal is linearly with DHZS concentration in the range of 0.01-3.0 microg mL(-1) with a detection limit of 3.6 ng mL(-1). The method was applied to the analysis of DHZS in pharmaceutical preparations and compared well with the high-performance liquid chromatography (HPLC) method. The CL mechanism is discussed and it is postulated that it involves nitrosoperoxocarboxylate (ONOOCO(2)(-)), which is an unstable adduct and can rapidly decompose into *NO(2) and *CO(3)(-) radical. The latter can then oxidize DHZS to give out strong CL emission.
[Mh] Termos MeSH primário: Dióxido de Carbono/química
Di-Hidralazina/análise
Di-Hidralazina/química
Luminescência
Ácido Peroxinitroso/química
[Mh] Termos MeSH secundário: Calibragem
Carbonatos/química
Catálise
Cromatografia Líquida de Alta Pressão/instrumentação
Cromatografia Líquida de Alta Pressão/métodos
Análise de Injeção de Fluxo/métodos
Radicais Livres/química
Peróxido de Hidrogênio/química
Estrutura Molecular
Nitritos/química
Ácido Nitroso/química
Oxirredução
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Carbonates); 0 (Free Radicals); 0 (Nitrites); 142M471B3J (Carbon Dioxide); 14691-52-2 (Peroxynitrous Acid); 45P3261C7T (sodium carbonate); BBX060AN9V (Hydrogen Peroxide); PCU411F5L6 (Dihydralazine); T2I5UM75DN (Nitrous Acid)
[Em] Mês de entrada:0808
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080517
[St] Status:MEDLINE
[do] DOI:10.1016/j.aca.2008.04.032


  9 / 387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:18434388
[Au] Autor:Piecha G; Koleganova N; Gross ML; Geldyyev A; Adamczak M; Ritz E
[Ad] Endereço:Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany. g.piecha@gmx.de
[Ti] Título:Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.
[So] Source:Am J Physiol Renal Physiol;295(1):F137-44, 2008 Jul.
[Is] ISSN:1931-857X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Angiotensin II accelerates and renin-angiotensin system blockade halts progression; blockade with high doses even reverses established glomerulosclerosis. Aldosterone also accelerates progression of glomerulosclerosis, partially independently of angiotensin II. The purpose of this study was to assess the relative ability of an angiotensin receptor type 1 (AT1) blocker, a mineralocorticoid receptor blocker, and their combination to reverse glomerulosclerosis. Sprague-Dawley rats were subjected to subtotal renal ablation (SNX) or sham operation. Eight weeks after surgery, they were either euthanized or allocated to treatment with vehicle, losartan, spironolactone, their combination, or unspecific antihypertensive treatment (dihydralazine) for 4 wk. Renal morphology was evaluated by stereology in tissues obtained using pressure-controlled perfusion fixation. Systolic blood pressure was significantly higher in SNX compared with sham-operated animals and decreased in all treatment groups. Compared with wk 8 after SNX, the glomerulosclerosis index (GSI) had increased further by week 12 in the vehicle- and dihydralazine-treated groups but was significantly lowered in the SNX+losartan as well as in the SNX+losartan+spironolactone groups and had not progressed further in the SNX+spironolactone group. The study confirms the partial regression of established glomerulosclerosis in subtotally nephrectomized rats after high-dose AT1 receptor blockade. Nonhyperkalemic doses of spironolactone prevented the increase but failed to decrease the GSI below the 8-wk level and preserved podocyte numbers. Combining the AT1 blocker with mineralocorticoid receptor blockade failed to further increase the regression of glomerulosclerosis.
[Mh] Termos MeSH primário: Glomerulonefrite/tratamento farmacológico
Losartan/uso terapêutico
Espironolactona/uso terapêutico
[Mh] Termos MeSH secundário: Albuminúria/urina
Bloqueadores do Receptor Tipo 1 de Angiotensina II/administração & dosagem
Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico
Animais
Colágeno Tipo IV/biossíntese
Desmina/biossíntese
Di-Hidralazina/uso terapêutico
Quimioterapia Combinada
Glomerulonefrite/patologia
Imuno-Histoquímica
Glomérulos Renais/patologia
Losartan/administração & dosagem
Masculino
Antagonistas de Receptores de Mineralocorticoides/administração & dosagem
Antagonistas de Receptores de Mineralocorticoides/uso terapêutico
NF-kappa B/biossíntese
Nefrectomia
Fator de Crescimento Derivado de Plaquetas/biossíntese
Ratos
Ratos Sprague-Dawley
Espironolactona/administração & dosagem
Fator de Crescimento Transformador beta1/biossíntese
Fator A de Crescimento do Endotélio Vascular/biossíntese
Receptor 2 de Fatores de Crescimento do Endotélio Vascular/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Angiotensin II Type 1 Receptor Blockers); 0 (Collagen Type IV); 0 (Desmin); 0 (Mineralocorticoid Receptor Antagonists); 0 (NF-kappa B); 0 (Platelet-Derived Growth Factor); 0 (Transforming Growth Factor beta1); 0 (Vascular Endothelial Growth Factor A); 0 (platelet-derived growth factor AB); 0 (vascular endothelial growth factor A, rat); 27O7W4T232 (Spironolactone); EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2); JMS50MPO89 (Losartan); PCU411F5L6 (Dihydralazine)
[Em] Mês de entrada:0808
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:080425
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00065.2008


  10 / 387 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:18098350
[Au] Autor:Valensise H; Vasapollo B; Novelli GP; Giorgi G; Verallo P; Galante A; Arduini D
[Ad] Endereço:Department of Obstetrics and Gynecology, Perinatal Medicine, Frascati (Rome), Rome, Italy. valensise@med.uniroma2.it
[Ti] Título:Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery.
[So] Source:Ultrasound Obstet Gynecol;31(1):55-64, 2008 Jan.
[Is] ISSN:0960-7692
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the effect of plasma volume expansion (PVE) and nitric oxide (NO) donors, in addition to antihypertensive therapy for gestational hypertensive pregnancies complicated by intrauterine growth restriction (IUGR) with absent end-diastolic flow (AEDF) in the umbilical artery (UA). METHODS: This was a case-control study into which 32 gestational hypertensive pregnancies with IUGR and AEDF were enrolled. Sixteen of these were treated with antihypertensive drugs, NO donors and PVE (Group A), and 16, matched for maternal age, gestational age and fetal conditions, were treated with antihypertensive drugs only (Group B). All patients underwent fetal and uteroplacental assessment and maternal echocardiography to evaluate total vascular resistance (TVR) and cardiac output before and 5-14 days after initiation of treatment. RESULTS: After 5-14 days of treatment, the maternal TVR in Group A fell from 2170 +/- 248 to 1377 +/- 110 dynes.s.cm(-5) (P < 0.01), and that in Group B fell from 2090 +/- 260 to 1824 +/- 126 dynes.s.cm(-5) (P < 0.01), with the reduction being greater in Group A than in Group B (P < 0.01). There was a significant increase in cardiac output in Group A after 5-14 days of treatment vs. baseline (6.19 +/- 0.77 vs. 4.32 +/- 0.66, P < 0.001), and, after treatment, cardiac output was significantly greater in Group A than it was in Group B (6.19 +/- 0.77 vs. 4.70 +/- 0.44, P < 0.001). Reappearance of end-diastolic flow in the UA occurred in 14/16 patients in Group A but in no patients in Group B (87.5% vs. 0%, P < 0.05). The interval between detection of UA-AEDF and delivery was 28 +/- 16 days in Group A and 11 +/- 6 days in Group B (P < 0.05). CONCLUSION: Administration of NO donors and PVE in gestational hypertensive pregnancies affected by IUGR and UA-AEDF appears to improve both maternal and fetal hemodynamics, inducing prolongation of gestation.
[Mh] Termos MeSH primário: Anti-Hipertensivos/uso terapêutico
Retardo do Crescimento Fetal/diagnóstico por imagem
Hipertensão Induzida pela Gravidez/tratamento farmacológico
Doadores de Óxido Nítrico/uso terapêutico
Artérias Umbilicais/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Anti-Hipertensivos/administração & dosagem
Velocidade do Fluxo Sanguíneo/efeitos dos fármacos
Velocidade do Fluxo Sanguíneo/fisiologia
Estudos de Casos e Controles
Di-Hidralazina/administração & dosagem
Di-Hidralazina/uso terapêutico
Ecocardiografia Doppler/métodos
Feminino
Hemodinâmica/efeitos dos fármacos
Hemodinâmica/fisiologia
Seres Humanos
Doadores de Óxido Nítrico/administração & dosagem
Circulação Placentária/efeitos dos fármacos
Circulação Placentária/fisiologia
Volume Plasmático/fisiologia
Gravidez
Artérias Umbilicais/anormalidades
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Nitric Oxide Donors); PCU411F5L6 (Dihydralazine)
[Em] Mês de entrada:0805
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:071222
[St] Status:MEDLINE



página 1 de 39 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde